Kevin Matthew Flanigan MD

Neuromuscular Medicine

Director, Center for Gene Therapy, and Robert F. & Edgar T. Wolfe Foundation Endowed Chair in Neuromuscular Research, Nationwide Children’s Hospital; Professor of Pediatrics and Neurology at the Ohio State University College of Medicine

Join to view full profile

555 S 18th StColumbus, OH 43205
Phone+1 614-722-6200

Dr. Flanigan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Flanigan's full profile Already have an account?

Education & Training

Johns Hopkins UniversityFellowship, Neuromuscular Medicine (Neurology), 1994 - 1995
Johns Hopkins UniversityResidency, Neurology, 1991 - 1994
University of MichiganInternship, Internal Medicine, 1990 - 1991
Rush Medical College of Rush University Medical CenterClass of 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2010 - 2027
UT State Medical License 1995 - 2010
MI State Medical License 1990 - 1991
American Board of Psychiatry and Neurology Neurology
American Board of Psychiatry and Neurology Neuromuscular Medicine

Clinical Trials

Finding the Optimum Regimen for Duchenne Muscular Dystrophy
COMPLETED
PHASE3
A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects Start of enrollment: 2013 May 01
TERMINATED
PHASE3
Natural History Studies of Mucopolysaccharidosis III
COMPLETED

Publications & Presentations

PubMed

Generation of an induced pluripotent stem cell line (NCHi026-A) from a patient with a partial deletion of exon 55 in the DMD gene.
Hui Lin, Stefan Nicolau, Kayla Stevens, Tatyana A Vetter, Sarah Atkins
Stem Cell Research. 2026-08-01
Unraveling the spatial landscape of dystrophinopathies: a transcriptomic approach to Becker and Duchenne muscular dystrophies.
Laura Gm Heezen, Qirong Mao, Stefan Nicolau, Claudio Novella Rausell, Julia van der Weerd
The Journal of Pathology. 2026-07-01
Gene x environment interaction analysis confirms genetic modifier effects on steroid efficacy via TGF-β pathway in Duchenne muscular dystrophy.
Veronica J Vieland, Sang-Cheol Seok, Megan A Waldrop, Leigh M Gabel, Diane M Dunn
European Journal of Human Genetics. 2026-07-01

Press Mentions

Nationwide Children's Names Gene Therapy Center for Retired Pioneer Dr. Jerry MendellSeptember 13th, 2024
Can Gene Editing Kill Deadly Diseases?April 11th, 2023
Muscular Dystrophy Association Virtual Conference to Feature Latest Advances in Neuromuscular Therapy and Clinical CareMarch 8th, 2021

Grant Support

Training Program in Basic and Translational Gene Therapy ResearchRESEARCH INST NATIONWIDE CHILDREN'S HOSP2026–2031
MDSRC for Next Directions in Muscular Dystrophy ResearchRESEARCH INST NATIONWIDE CHILDREN'S HOSP2024–2028
Preclinical development of DMD exon 44 skipping using AAV.U7snRNA: a versatile tool that can help 6-12% of DMD patientRESEARCH INST NATIONWIDE CHILDREN'S HOSP2025–2027
Molecular Mechanisms of Dystrophin Expression in Ameliorated PhenotypesRESEARCH INST NATIONWIDE CHILDREN'S HOSP2023–2027
Genetic modifiers of Duchenne Muscular DystrophyRESEARCH INST NATIONWIDE CHILDREN'S HOSP2014–2027